IDH1 and cholangiocarcinoma: Ivosidenib (AG-120) is an oral, potent, targeted inhibitor of the mutant IDH1 (mIDH1) enzyme that is approved for the treatment of patients with locally advanced or metastatic cholangiocarcinoma, and subsets of adult patients with acute myeloid leukemia, with a susceptible IDH1 mutation [11].